Avacta is the proprietary owner of Affimer technology for the development of biotherapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which dominates the drug industry despite its limitations. During 2016, Avacta made considerable progress towards its strategic goal to have a first-in-man Affimer therapeutic by the end of 2019. During coming weeks the company is expected to report on the next step in the pre-clinical development process: whether or not Affimer scaffolds are immunogenic. A positive outcome would be a low immune response rate.
21 Mar 2017
Low response would be positive!
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Low response would be positive!
Avacta Group PLC (AVCT:LON) | 44.8 0 0.0% | Mkt Cap: 160.7m
- Published:
21 Mar 2017 -
Author:
Martin Hall -
Pages:
8
Avacta is the proprietary owner of Affimer technology for the development of biotherapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which dominates the drug industry despite its limitations. During 2016, Avacta made considerable progress towards its strategic goal to have a first-in-man Affimer therapeutic by the end of 2019. During coming weeks the company is expected to report on the next step in the pre-clinical development process: whether or not Affimer scaffolds are immunogenic. A positive outcome would be a low immune response rate.